Ryosuke Sugimoto, Motoh Iwasa, Nagisa Hara, Yasuyuki Tamai, Kyoko Yoshikawa, Suguru Ogura, Hideaki Tanaka, Akiko Eguchi, Norihiko Yamamoto, Yoshinao Kobayashi, Hiroshi Hasegawa, Yoshiyuki Takei
AIM: Management of low skeletal muscle mass (LSM) is a very important topic as LSM affects patient mortality in liver diseases. Changes in body composition are unexplored in chronic hepatitis C virus (HCV) patients, including those with liver cirrhosis, who receive direct-acting antiviral (DAA) therapy. Body composition measurements and liver function tests were carried out before and after DAA therapy. METHODS: Blood examination, visceral fat area (VFA) and extremity skeletal muscle mass were measured using the multifrequency bioelectrical impedance analysis method: (i) at 24 weeks before DAA therapy; (ii) at the start of DAA therapy; (iii) at the end of DAA therapy; (iv) at 24 weeks after DAA therapy; and (v) at 48 weeks after DAA therapy...
November 8, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology